Three Ways a Pulmonary Fibrosis Lung Health Navigator Can Support You - American Lung Association

Fibrosis, the dense scar tissue that can entangle peritoneal tumors and the healthy organs around them, is one reason cytoreduction surgery is denied to a portion of patients with appendiceal and other abdominal cancers. Allegheny Health Network Cancer Center’s newly launched RANDY’S Trial is built on a direct answer to that problem: test whether FDA-approved drugs already on the market can remodel that scar tissue and bring more patients into surgical eligibility. The trial did not emerge from a pharma pipeline or an NIH grant. A single community gala, the La Sera d’Oro event, raised $44,000 in 2025 to fund it. The acronym stands for Repurposed And Naturally-Derived Drugs for the Treatment of Fibrosis in Peritoneal Carcinomatosis. Principal investigator Patrick Wagner, a surgical oncologist at AHN, is leading a multidisciplinary team that will evaluate existing medications for their ability to break down or remodel abdominal scar tissue. The mechanism matters because fibrosis does two things that complicate surgery: it obscures the boundary between healthy and diseased tissue, and it can trap cancer cells that are then left behind when a surgeon separates planes.

A lung affected by deadly forms of COVID-19 not only loses essential cells for breathing but also undergoes profound changes in its internal organization and the way its cells communicate with each other. A study involving the Sant Pau Research Institute (IR Sant Pau), published in Nature Communications, has created a spatial map of this transformation and identified some of the molecular mechanisms that accompany the progression of lung damage and fibrosis.

Demand for electrification is moving faster than the system it connects to. Electric vehicles, heat pumps and electrified industrial processes are scaling1, and the the United Nations Climate Change Conference (COP31) Presidency has set a global target of 35% of final energy demand met by electricity by 2035, up from around 21% today.2 What now sets the pace is the readiness of the power system, which means how fast projects connect, whether prices reward flexibility, and whether equipment and markets work together. For businesses, electrification is increasingly a decision about competitiveness, resilience and long-term value creation. The companies and markets that can electrify faster are often better positioned to manage energy costs, access new revenue streams, strengthen operational resilience and attract investment. Businesses across every sector describe the same set of barriers: connection queues running for years, tariffs that do not support the business case and hold flat while system costs move hour by hour, fragmented market structures with missing aggregation rules and interoperability standards, and flexible capacity waiting for a market to sell into.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.